Ideaya Biosciences Inc (IDYA) Stock Price, Quote & News

Company Profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumor...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 443 6209

Website: www.ideayabio.com

Address:

5000 Shoreline Court, Suite 300, South San Francisco, United States

TheBiotechInvestor_ Feb. 20 at 11:21 PM

$IDYA $XBI

0 · Reply

50bps Feb. 19 at 4:39 PM

$IDYA 👀

0 · Reply

CH_Expat Feb. 19 at 2:51 PM

$IDYA Fishy price movement here. Little volume, a lot of price target upgrades, management overconfident before readout, 112% institutional ownership- and a drop from 40 to 30 on nothing but excellent news. Remember they can do whatever they want, it could stay flat even on homerun data, but it could also run back to 40 before data.

0 · Reply

CH_Expat Feb. 19 at 6:47 AM

$IDYA Can you afford to present bad data after this? https://seekingalpha.com/article/4871665-ideaya-biosciences-inc-idya-presents-at-citis-2026-virtual-oncology-leadership-summit

3 · Reply

CH_Expat Feb. 18 at 6:19 PM

$IDYA Added more. Hint: KOL-Breakfast at Cantor this morning.

1 · Reply

Quantumup Feb. 18 at 2:54 PM

Cantor reiterated Top Pick $IDYA at an Overweight rating heading into Ideaya's topline PFS readout from the Ph2/3 OptimUM-02 trial in 1L MUM (metastatic uveal melanoma) slated for the last week of March. $IMCR $REPL $BMY $PFE GILD AMGN GSK MRK DCTH Here's what Cantor said in its note to investors: https://x.com/Quantumup1/status/2024134420320374998?s=20

0 · Reply

erevnon Feb. 18 at 2:49 PM

Wedbush maintains IDEAYA Biosciences $IDYA at Outperform and raises the price target from $49 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

CH_Expat Feb. 18 at 9:44 AM

$IDYA Baker Bros increased their position by 11% as per their latest filing from February 17th.

1 · Reply

CH_Expat Feb. 17 at 7:33 PM

$IDYA From Jerome Leonard on X.

0 · Reply

Popal Feb. 17 at 7:20 PM

$IDYA

0 · Reply

IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

Feb 18, 2026, 3:44 PM EST - 4 days ago

IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Feb 17, 2026, 6:00 AM EST - 6 days ago

IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Feb 2, 2026, 6:00 AM EST - 21 days ago

IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events

Jan 30, 2026, 6:00 AM EST - 24 days ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jan 13, 2026, 1:45 AM EST - 5 weeks ago

IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 12:00 PM EST - 6 weeks ago

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 6:00 AM EST - 7 weeks ago

IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 6:00 AM EST - 2 months ago

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

Dec 10, 2025, 6:00 AM EST - 2 months ago

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

Dec 4, 2025, 7:00 PM EST - 2 months ago

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

Dec 2, 2025, 5:43 PM EST - 2 months ago

IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 1, 2025, 6:00 AM EST - 3 months ago

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

Nov 25, 2025, 4:58 PM EST - 3 months ago

Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away

Nov 24, 2025, 6:00 AM EST - 3 months ago

IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events

Nov 6, 2025, 7:06 PM EST - 3 months ago

IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2025 SMID Cap Biopharma Call Series Transcript

Nov 4, 2025, 6:00 AM EST - 3 months ago

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 27, 2025, 6:00 AM EDT - 4 months ago

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

Oct 20, 2025, 6:30 AM EDT - 4 months ago

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025

Oct 20, 2025, 6:00 AM EDT - 4 months ago

IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Sep 8, 2025, 6:41 PM EDT - 5 months ago

IDEAYA Biosciences, Inc. (IDYA) 10-Year Anniversary R&D Day (Transcript)

Sep 8, 2025, 4:30 PM EDT - 5 months ago

IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst

Sep 8, 2025, 8:00 AM EDT - 6 months ago

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

Sep 8, 2025, 6:00 AM EDT - 6 months ago

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

Sep 7, 2025, 12:00 PM EDT - 6 months ago

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

Sep 4, 2025, 6:00 AM EDT - 6 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

Sep 3, 2025, 10:15 PM EDT - 6 months ago

IDEAYA Biosciences, Inc. (IDYA) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 6:00 AM EDT - 6 months ago

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

Sep 2, 2025, 6:00 AM EDT - 6 months ago

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

Aug 29, 2025, 2:00 PM EDT - 6 months ago

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Aug 25, 2025, 6:00 AM EDT - 6 months ago

IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events

Aug 18, 2025, 6:00 AM EDT - 6 months ago

IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025

Aug 5, 2025, 8:43 AM EDT - 7 months ago

Ideaya Biosciences: Moving Into ADCs For Solid Tumors

Aug 5, 2025, 6:00 AM EDT - 7 months ago

IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 24, 2025, 9:25 AM EDT - 7 months ago

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

Jul 23, 2025, 6:00 AM EDT - 7 months ago

IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy

Jul 22, 2025, 1:01 PM EDT - 7 months ago

IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

Jul 21, 2025, 6:00 AM EDT - 7 months ago

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event

Jun 2, 2025, 6:00 AM EDT - 9 months ago

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

May 14, 2025, 5:30 PM EDT - 10 months ago

Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849

May 6, 2025, 6:05 AM EDT - 10 months ago

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 6:00 AM EDT - 10 months ago

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

Apr 28, 2025, 6:00 AM EDT - 10 months ago

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

Apr 16, 2025, 8:52 AM EDT - 11 months ago

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later

Apr 14, 2025, 6:00 AM EDT - 11 months ago

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

Apr 10, 2025, 6:00 AM EDT - 11 months ago

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

Apr 2, 2025, 11:12 AM EDT - 11 months ago

Why Ideaya Biosciences Is Down Despite Many Positives

Apr 1, 2025, 6:00 AM EDT - 11 months ago

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events

Mar 31, 2025, 6:00 AM EDT - 11 months ago

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

Mar 26, 2025, 6:00 AM EDT - 11 months ago

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor

Mar 3, 2025, 6:00 AM EST - 1 year ago

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

TheBiotechInvestor_ Feb. 20 at 11:21 PM

$IDYA $XBI

0 · Reply

50bps Feb. 19 at 4:39 PM

$IDYA 👀

0 · Reply

CH_Expat Feb. 19 at 2:51 PM

0 · Reply

CH_Expat Feb. 19 at 6:47 AM

$IDYA Can you afford to present bad data after this? https://seekingalpha.com/article/4871665-ideaya-biosciences-inc-idya-presents-at-citis-2026-virtual-oncology-leadership-summit

3 · Reply

CH_Expat Feb. 18 at 6:19 PM

$IDYA Added more. Hint: KOL-Breakfast at Cantor this morning.

1 · Reply

Quantumup Feb. 18 at 2:54 PM

0 · Reply

erevnon Feb. 18 at 2:49 PM

Wedbush maintains IDEAYA Biosciences $IDYA at Outperform and raises the price target from $49 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

CH_Expat Feb. 18 at 9:44 AM

$IDYA Baker Bros increased their position by 11% as per their latest filing from February 17th.

1 · Reply

CH_Expat Feb. 17 at 7:33 PM

$IDYA From Jerome Leonard on X.

0 · Reply

Popal Feb. 17 at 7:20 PM

$IDYA

0 · Reply

CH_Expat Feb. 17 at 4:00 PM

$IDYA Now that we have a date for the readout, we have five more weeks. I expect serious MM games here and have dry powder ready for it. Since I still do not find better options, I might as well go almost all in here. Was not expecting to see below 30s.

1 · Reply

DonCorleone77 Feb. 17 at 11:21 AM

$IDYA Ideaya Biosciences reports Q4 EPS (94c), consensus (95c) Reports Q4 revenue $10.88M, consensus $5.95M. Collaboration revenue was recognized for the performance obligations satisfied through December 31, 2025 related to the research and development services that are recognized over time under the Servier exclusive license agreement for darovasertib. "We had a strong quarter of clinical execution, clinical pipeline expansion and commercial readiness activities. The key highlights include completing full enrollment of 437 patients in OptimUM-02, our Phase 2/3 registrational trial in first line HLA*A2-negative mUM, submission of IND filings for IDE034, a potential first-in-class B7H3/PTK7 bispecific TOP1 ADC, and IDE574, a KAT6/7 dual inhibitor, and continued build out of our U.S. commercial organization in anticipation of our upcoming topline PFS results," said Yujiro Hata, president and CEO, Ideaya Biosciences.

0 · Reply

OfficialStocktwitsUser Feb. 16 at 3:50 PM

$IDYA RSI: 32.17, MACD: -0.9574 Vol: 1.69, MA20: 33.57, MA50: 34.47 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

CH_Expat Feb. 13 at 9:04 PM

$IDYA Always a recovery in the final 15 minutes on low volume down days. I was in many stocks (BPMC, MYOV, ARWR, SWTX) that showed a similar behavior weeks before important news (Approval decision, P3 results). All the stuff turned out positive in the end.

0 · Reply

CH_Expat Feb. 13 at 8:49 PM

$IDYA POS is 90% as per Lifesci, as per IDYA-Mastermind Jerome Leonard 99% Expecting 8-8.5m of mpfs. Some people dream of 9. Even if it is only 7, we have a delta of at least 4 months compared to Kimmtrak. Not too shabby. If there was less manipulation, I would buy much more. Next badge in 28s.

0 · Reply

JFais Feb. 13 at 4:08 PM

$IDYA back on DD list, dips to mid $20S where gets more interesting IMO

1 · Reply

CH_Expat Feb. 13 at 3:55 PM

$IDYA Vicious opening selloffs followed by a light recovery - all on low volume prior to the most important readout in the company history. Wow, creative. We have never seen this before.

0 · Reply

CDMO Feb. 13 at 2:45 PM

$IDYA damn my order below 30 didn't get filled

1 · Reply

Hottehueh Feb. 13 at 2:45 PM

$IDYA bought this dip

0 · Reply

CH_Expat Feb. 12 at 3:59 PM

$IDYA Where are you guys? @WSRX @RonIsWrong @jwon3 @himsssss ? All long and strong? Getting a bit autistic here from my side.

4 · Reply

CH_Expat Feb. 12 at 3:30 PM

$IDYA 110,38% institutional ownership. Are you smarter than they are?

1 · Reply

CH_Expat Feb. 11 at 6:48 PM

$IDYA Our CEO served for Onyx, Flexus and RAPT. Just in case you were not aware.

0 · Reply

Market Cap	2.81B
Revenue (ttm)	7.00M
Net Income (ttm)	-274.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,921.14%
Debt to Equity Ratio	0.00

Volume	805,700
Avg Vol	902,818
Day's Range	N/A - N/A
Shares Out	87.81M
Stochastic %K	60%
Beta	0.10
Analysts	Strong Sell
Price Target	$50.76